Microsatellite instability (MSI) is a condition in which a tumor’s DNA repair system is broken, causing small, repetitive sequences of DNA to accumulate errors as the cancer cells divide. These errors make the tumor genetically unstable, which sounds bad but actually has a major upside: tumors with high levels of microsatellite instability tend to respond remarkably well to immunotherapy and, in some cancers, carry a better prognosis than their stable counterparts.
Understanding MSI has become one of the most practical advances in cancer care over the past decade. It affects treatment decisions, helps identify inherited cancer syndromes, and can change a patient’s outlook significantly.
How DNA Repair Normally Works
Every time a cell divides, it copies its entire DNA. That process isn’t perfect. Small errors slip in, especially in microsatellites, which are short stretches of DNA where the same one to six letters repeat over and over. These repetitive sections are prone to a copying glitch called strand slippage, where the copying machinery accidentally adds or skips a repeat.
Healthy cells fix these mistakes with a system called mismatch repair. The process works in two steps. First, a pair of proteins detects the error by scanning newly copied DNA for mismatches and small insertions or deletions. Then a second pair of proteins cuts the faulty section so it can be replaced with the correct sequence. When any of these proteins stop functioning, copying errors in microsatellites pile up with each cell division, and the microsatellites grow longer or shorter than they should be. That accumulation of uncorrected errors is microsatellite instability.
What Causes the Repair System to Fail
The mismatch repair system can break down in two main ways. The more common route in colorectal cancer is sporadic: a chemical modification called methylation silences one of the key repair genes in the tumor itself. Between 10% and 15% of colorectal cancers become MSI-high through this mechanism, with no inherited component at all.
The second route is inherited. Lynch syndrome is a genetic condition in which a person is born with a faulty copy of one of the mismatch repair genes in every cell. If the remaining working copy is lost in a particular tissue, the repair system shuts down and cancer can develop. Lynch syndrome accounts for roughly 3% of colorectal cancers and 3% of endometrial cancers. Identifying MSI in a tumor is one of the primary ways Lynch syndrome gets detected, which is why testing has become routine.
How Common MSI Is Across Cancer Types
MSI doesn’t occur at the same rate in every cancer. Endometrial cancer has the highest prevalence, with 20% to 40% of cases showing mismatch repair deficiency. Colorectal cancer follows at 10% to 15%. Small bowel adenocarcinoma falls in the 10% to 30% range, and gastroesophageal cancer sits around 10%. For most other solid tumors, the rate drops to about 4%.
These numbers matter because MSI status can shift the entire treatment approach. A patient with an MSI-high gastric cancer, for instance, may be a candidate for immunotherapy that wouldn’t typically be offered for that cancer type.
MSI-High, MSI-Low, and Microsatellite Stable
Tumors are classified into three categories based on how many microsatellite markers show instability when tested. The standard panel examines five specific markers. If two or more of those five are unstable, the tumor is classified as MSI-high. If only one marker is unstable, it’s considered MSI-low (sometimes called MSI-indeterminate). If none of the markers show changes, the tumor is microsatellite stable.
The distinction that matters most clinically is between MSI-high and everything else. MSI-low tumors generally behave like microsatellite stable tumors in terms of treatment response and prognosis, so the practical divide is really MSI-high versus non-MSI-high.
How MSI Testing Works
Three main methods are used to determine a tumor’s MSI status, each with different strengths.
- Immunohistochemistry (IHC) is the most widely used approach. A pathologist stains a thin slice of tumor tissue with antibodies that bind to the four main mismatch repair proteins. If one or more proteins are missing, the repair system is considered deficient. IHC is cost-effective and available at most pathology labs, but it can produce ambiguous results, and some MSI-high tumors lose repair function through mechanisms that IHC won’t catch.
- PCR-based testing directly measures whether microsatellite sequences have changed length compared to normal tissue. This was the original method for MSI detection and remains reliable for colorectal and endometrial cancers. It becomes less accurate in other cancer types, partly because the standard marker panels were designed with those two cancers in mind.
- Next-generation sequencing (NGS) analyzes a much larger number of microsatellite regions alongside other genetic information, all from a single tissue sample. This makes it particularly useful when comprehensive genomic profiling is already being done, and it avoids some of the limitations of PCR in less common tumor types.
The National Comprehensive Cancer Network recommends universal MSI or mismatch repair testing for all patients with colorectal or endometrial cancer, regardless of age or family history. This serves a dual purpose: guiding treatment decisions and screening for Lynch syndrome.
Why MSI-High Tumors Respond to Immunotherapy
The same genetic chaos that defines MSI-high tumors also makes them vulnerable to the immune system. All those uncorrected DNA errors produce abnormal proteins on the surface of cancer cells, essentially waving flags that immune cells can recognize. MSI-high tumors typically have a high “mutational burden,” meaning they carry far more mutations than stable tumors. More mutations mean more abnormal proteins, and more abnormal proteins mean more targets for immune attack.
The problem is that cancers learn to hide from the immune system by activating a molecular brake called PD-1. Immunotherapy drugs called checkpoint inhibitors release that brake. In MSI-high colorectal cancer, one such drug produced an overall response rate of 43.8%, compared to 33.1% for standard chemotherapy. Even more striking, 83% of patients who responded to immunotherapy still had ongoing responses at two years, compared to just 35% of chemotherapy responders. These results led to FDA approval of checkpoint inhibitors specifically for MSI-high cancers, initially for colorectal cancer and later expanded to any MSI-high solid tumor.
MSI and Prognosis in Early-Stage Colon Cancer
Beyond immunotherapy, MSI status carries important prognostic information, particularly in stage II colon cancer. In a study of nearly 17,000 patients with resected stage II disease, those with MSI-high tumors had a five-year overall survival of 83%, compared to 76% for patients with stable or MSI-low tumors.
The survival advantage held up even when tumors had features that typically signal a worse outlook. Patients with MSI-high tumors that had spread into lymph vessels had a five-year survival of 85%, compared to 69% for patients with the same feature in stable tumors. When cancer had invaded surrounding nerves, the gap was 75% versus 59%. MSI-high tumors with high-risk features performed as well as stable tumors with no high-risk features, both landing at 80% five-year survival.
Within the MSI-high group, only two factors were associated with worse outcomes: tumors that had grown through the full thickness of the colon wall (T4 stage) and tumors with positive surgical margins. Other features that typically predict poor outcomes in stable tumors, like spread into lymph vessels or fewer than 12 lymph nodes examined, did not affect survival in MSI-high patients. This finding has practical implications for treatment planning, since it may influence whether adjuvant chemotherapy is recommended after surgery.
What MSI Testing Means for You
If you or someone you know has been diagnosed with colorectal or endometrial cancer, MSI testing is now a standard part of the workup. The result provides three pieces of information at once: whether immunotherapy is likely to work, what the general prognosis looks like, and whether there’s a possible inherited cancer syndrome that family members should know about.
An MSI-high result doesn’t automatically mean Lynch syndrome is present. The majority of MSI-high colorectal cancers are sporadic, caused by changes that happened only in the tumor. Additional testing, typically looking for methylation of the repair gene promoter or for a specific mutation associated with sporadic cases, helps distinguish between the two. If Lynch syndrome is confirmed, first-degree relatives can be offered genetic testing and, if positive, enhanced cancer screening that has been shown to catch cancers earlier.